首页>投融资
Oxford Endovascular
A+轮
Oxford Endovascular Ltd.是牛津大学的一家分公司,致力于通过治愈脑动脉瘤来预防脑出血,这种疾病影响每50人中的1人。OxiFlow™️是一种新型的下一代分流器,可将血流从颅内动脉瘤转移开,有破裂风险。它比现有设备更准确、更安全地放置,从而降低了发生并发症的风险。它更好地适应血管,使更多患者可以接受治疗。它由近30年来在动脉瘤治疗领域首创的世界知名医师发明,在欧洲、美国、中国和日本拥有专利。该公司已经筹集了超过1000万美元以支持其发展,包括在经过医疗、行业和投资者专家的广泛尽职调查后,获得了欧盟颁发的著名的Horizon 2020赠款。瞄准快速增长的超过10亿美元的市场,Oxford Endovascular可满足尚未满足的临床需求,因此有望实现显著增值。
基本信息
-
公司全称Oxford Endovascular Ltd
-
类型治疗类设备研发商
-
产业领域医疗器械、治疗设备
-
公司人数15人以下
-
地址Oxford Science Park
-
联系电话
-
邮箱mkarim@oxfordendovascular.com
-
成立时间2015-01-01
投融资
-
2024-05-20A+轮800万英镑Parkwalk AdvisorsUniversity of OxfordVulpes investment ManagementOxford Science EnterprisesNorcliffe Capital
-
2021-04-08A轮1000万美元Vulpes investment ManagementOxford Investment ConsultantsOxford Sciences InnovationParkwalk AdvisorsUniversity of OxfordPerivoli InnovationsAdditio investment Group
-
2020-07-09未透露550万欧元EIT Health
-
2018-05-01未透露250万英镑Parkwalk AdvisorsPerivoli InnovationsOxford Investment Consultants
- 加载更多
相关投融资企业
C轮
Francis Medical is a dynamic medical device company committed to developing urological cancer treatments that are tough on cancer yet gentle on patients.In September 2020, Coloplast announced that it has completed a USD 4m (DKK 25m) equity investment in Francis Medical
收并购
Gynesonics is a developer of transcervical, uterus-preserving, incision-free technologies for diagnostic and therapeutic applications (avoiding invasive surgical techniques of hysterectomy or myomectomy for symptomatic uterine fibroids). Products include the Sonata system which combines intrauterine ultrasound guidance with targeted radiofrequency ablation.In April 2023, the company closed a financing round of $25M
未公开
BetaGlue Therapeutics是一家临床分期肿瘤公司,该公司开发了一种先进的放疗平台,能够对不可切除的实体瘤和手术切缘进行局部靶向治疗,称为YntraDose。